AUSTIN, Texas and HAMILTON, ON and SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 /PRNewswire/ -- Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that it will participate with one oral presentation and four posters at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting in San Diego, California, from November 1-5.

奥斯汀，德克萨斯州和汉密尔顿，安大略省和南旧金山，加利福尼亚州，2023年10月30日/PRNewswire/-Triumvira Immunologics，一家临床阶段公司，开发新型，靶向自体和同种异体T细胞疗法，共同选择天然生物学T细胞治疗实体瘤患者，今天宣布，它将于11月1日至5日在加利福尼亚州圣地亚哥举行的2023年癌症免疫治疗学会（SITC）年会上发表一次口头报告和四张海报。

The company will showcase clinical and preclinical data across various programs, including its ongoing Phase I/II study investigating the safety and efficacy of autologous TAC-T cells targeting human epidermal growth factor receptor 2 (HER2) in relapsed or refractory solid tumors (TACTIC-2 /NCT04727151) and its CLDN18.2, GUCY2C and allogeneic TAC T cell technologies..

该公司将展示各种项目的临床和临床前数据，包括正在进行的I/II期研究，研究靶向人表皮生长因子受体2（HER2）的自体TAC-T细胞在复发或难治性实体瘤中的安全性和有效性（TACTIC-2/NCT04727151）及其CLDN18.2，GUCY2C和同种异体TAC T细胞技术。。

TAC01-HER2 is an innovative cell-based therapy that involves the utilization of genetically modified T cells derived from the patient themselves. These cells express a T-cell Antigen Coupler (TAC) which is designed to specifically recognize HER2 in tumors. In addition to the TAC01-HER2 candidate, the company is investigating TAC-GUCY2C for the treatment of colorectal cancer and TAC01-CLDN18.2 for the treatment of pancreatic ductal adenocarcinoma and gastric cancer..

TAC01-HER2是一种基于细胞的创新疗法，涉及利用源自患者自身的转基因T细胞。这些细胞表达T细胞抗原偶联剂（TAC），其被设计为特异性识别肿瘤中的HER2。除了TAC01-HER2候选药物外，该公司正在研究用于治疗结肠直肠癌的TAC-GUCY2C和用于治疗胰腺导管腺癌和胃癌的TAC01-CLDN18.2。。

'The new data we are presenting at SITC demonstrates the robustness of our TAC-T cells platform and its potential for precise targeting of malignant cells expressing tumor-associated antigens such as HER2, Claudin 18.2 and GUCY2C,' stated Dr. Paul Lammers, CEO of Triumvira Immunologics. 'Our commitment to developing innovative T cell therapeutics that harness the natural biology of T cells is supported by the promising preliminary results from our ongoing Phase I/II study targeting HER2 in solid tumors.

Paul Lammers博士说：“我们在SITC上提供的新数据证明了我们的TAC-T细胞平台的稳健性及其精确靶向表达肿瘤相关抗原（如HER2，Claudin 18.2和GUCY2C）的恶性细胞的潜力。”Triumvira Immunologics首席执行官“我们致力于开发利用T细胞天然生物学的创新性T细胞疗法，这得到了我们正在进行的针对实体瘤中HER2的I/II期研究的有希望的初步结果的支持。

In addition, we are advancing our pipeline by evaluating the clinical efficacy of TAC01-CLDN18.2, a novel autologous cell therapy that recognizes Claudin 18.2, a promising therapeutic target that is selectively over-expressed in gastric cancers and other solid tumors.'.

此外，我们正在通过评估TAC01-CLDN18.2的临床疗效来推进我们的管道，TAC01-CLDN18.2是一种新型自体细胞疗法，可识别Claudin 18.2，Claudin 18.2是一种在胃癌和其他实体瘤中选择性过表达的有希望的治疗靶点。

Details of the abstract oral presentation are as follows:

摘要口头陈述的细节如下：

Abstract Number: 654Title: A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumorsPresenter: Daniel Olson M.D., University of ChicagoSession: Concurrent Session 105b: Rapid Oral Abstracts - ClinicalDate: Friday, November 3 at 12:15 – 1:15 p.m.

摘要编号：654Title：一项I/II期临床试验，研究自体TAC01-HER2在复发或难治性实体瘤中的安全性和有效性主持人：Daniel Olson医学博士，ChicagoSession大学：同期会议105b：快速口服摘要-临床状态：周五，11月3日下午12:15-1:15。

Pacific TimeLocation: Ground Level, Exhibit Hall C, San Diego Convention Center.

太平洋时间：地面，展览厅C，圣地亚哥会议中心。

Details of the abstract poster presentations are as follows:

抽象海报演示文稿的细节如下：

Abstract Number: 347Title: Functional characterization of GUCY2C-TAC T cells for the treatment of colorectal cancer using preclinical modelsAuthors: Tania Benatar, Thanyashanthi Nitya-Nootan, Gargi Thakor, Suzanna Prosser, Philbert Ip, Prabha Lal, Alima Khan, Stacey Xu, Sailaja Pirati, Deepika Bhemarasetty, Christopher Helsen, Andreas BaderCategory: Cellular TherapiesDate: Friday, November 3 at 9 a.m.

摘要编号：347标题：使用临床前模型治疗结直肠癌的GUCY2C-TAC T细胞的功能表征作者：Tania Benatar，Thanyashanthi Nitya Nootan，Gargi Thakor，Suzanna Prosser，Philbert Ip，Prabha Lal，Alima Khan，Stacey Xu，Sailaja Pirati，Deepika Bhemarasetty，Christopher Helsen，Andreas BaderCategory：细胞疗法日期：周五，11月3日上午9点。

Pacific TimeLocation: Exhibit and Poster Hall (Exhibit Hall B), San Diego Convention Center.

太平洋时间：展览和海报厅（展览厅B），圣地亚哥会议中心。

Abstract Number: 372Title: TAC-T cells persist and remain functional during and after repeated tumor exposure in vitro and in vivoAuthors: Heather MacGregor, Suzanna Prosser, Stacey Xu, Kyle MacDonald, Aksha Kadri, Ritu Randhawa, Swati Shetty, Sailaja Pirati, Deepika Bhemarasetty, Christopher Helsen, Sadhak Sengupta, Andreas Bader Category: Cellular TherapiesDate: Saturday, November 4 at 9 a.m.

摘要编号：372标题：TAC-T细胞在体外和体内反复肿瘤暴露期间和之后持续存在并保持功能作者：Heather MacGregor，Suzanna Prosser，Stacey Xu，Kyle MacDonald，Aksha Kadri，Ritu Randhawa，Swati Shetty，Sailaja Pirati，Deepika Bhemarasetty，Christopher Helsen，Sadhak Sengupta，Andreas Bader类别：细胞治疗日期：11月4日星期六上午9点。

Pacific TimeLocation: Exhibit and Poster Hall (Exhibit Hall B), San Diego Convention Center.

太平洋时间：展览和海报厅（展览厅B），圣地亚哥会议中心。

Abstract Number: 400Title: Preclinical characterization and modeling of allogeneic Vγ9Vδ2 TAC T cells for the treatment of solid tumorsAuthors: Stacey Xu, Suzanna Prosser, Ling Wang, Ritu Randhawa, Sailaja Pirati, Deepika Bhemarasetty, Kyle MacDonald, Seung Mi Yoo, Miyoung Jung, Laurentia Gheorghiu, Chris Ayers, Sadhak Sengupta, Christopher Helsen, Andreas Bader Category: Cellular TherapiesDate: Saturday, November 4 at 9 a.m.

摘要编号：400标题：用于治疗实体瘤的同种异体Vγ9Vδ2TacT细胞的临床前表征和建模作者：Stacey Xu，Suzanna Prosser，Ling Wang，Ritu Randhawa，Sailaja Pirati，Deepika Bhemarasetty，Kyle MacDonald，Seung-Mi Yoo，Miyoung Jung，Laurentia Gheorghiu，Chris Ayers，Sadhak Sengupta，Christopher Helsen，Andreas Bader类别：细胞治疗日期：11月4日星期六上午9点。

Pacific TimeLocation: Exhibit and Poster Hall (Exhibit Hall B), San Diego Convention Center.

太平洋时间：展览和海报厅（展览厅B），圣地亚哥会议中心。

Abstract: Number 738Title: A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic claudin 18.2+ solid tumorsAuthors: Daniel Olson, Ecaterina Dumbrava, Sam Saibil, Martin Gutierrez, Syma Iqbal, Davendra Sohal, Maria Apostolopoulou, Kara Moss, Deyaa Adib, Benjamin SchlechterCategory: Clinical Trial In ProgressDate: Friday, November 3 at 9 a.m.

摘要：编号738标题：一项1/2期研究，调查自体TAC T细胞在不可切除，局部晚期或转移性claudin 18.2+实体瘤患者中的安全性和有效性作者：Daniel Olson，Ecaterina Dumbrava，Sam Saibil，Martin Gutierrez，Syma Iqbal，Davendra Sohal，Maria Apostolopoulou，Kara Moss，Deyaa Adib，Benjamin SchlechterCategory：进展期临床试验日期：周五，11月3日上午9点。

Pacific TimeLocation: Exhibit and Poster Hall (Exhibit Hall B), San Diego Convention Center.

太平洋时间：展览和海报厅（展览厅B），圣地亚哥会议中心。

About Triumvira ImmunologicsTriumvira Immunologics, Inc. ('Triumvira') is a leading clinical-stage solid tumor cell therapy company developing unique, non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors.

关于Triumvira ImmunologicsTriumvira Immunologics，Inc。（'Triumvira'）是一家领先的临床阶段实体肿瘤细胞治疗公司，开发独特的，非基因编辑的，一流的靶向自体和同种异体T细胞疗法，共同选择天然生物学T细胞治疗实体瘤患者。

The company's proprietary T cell Antigen Coupler (TAC) technology is a robust and versatile platform that activates natural T cell functions differently from cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies. Triumvira is developing a broad pipeline targeting promising tumor-associated antigens such as HER2, Claudin 18.2, GUCY2C and GPC3.

该公司专有的T细胞抗原偶联剂（TAC）技术是一个强大而多功能的平台，可激活天然T细胞功能，不同于细胞疗法，如CAR-T和工程化T细胞受体（TCR）疗法。Triumvira正在开发一条广泛的管道，针对有希望的肿瘤相关抗原，如HER2，Claudin 18.2，GUCY2C和GPC3。

Triumvira is headquartered in Austin, Texas, with research facilities in Hamilton, Ontario, and GMP manufacturing facilities in South San Francisco, California..

Triumvira总部设在德克萨斯州奥斯汀，在安大略省汉密尔顿拥有研究设施，在加利福尼亚州南旧金山拥有GMP生产设施。。

Media ContactDavid Schull or Ignacio Guerrero-Ros, Ph.D.Russo Partners858-717-2310646-942-5604[email protected][email protected]

媒体联系David Schull或Ignacio Guerrero Ros，Ph.D.Russo合作伙伴858-717-2310646-942-5604[电子邮件保护][电子邮件保护]

SOURCE Triumvira Immunologics

来源Triumvira免疫学